Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492680 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT07492680: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT07492680 is a Phase 2 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07492680, a Phase 2 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.
Primary Outcome
OR is defined as confirmed complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Response Assessment in Neuro-Oncology (RANO) v2 or Modified RECIST v1.1
Interventions
- DRUG Temozolomide
- DRUG Pumitamig
- DRUG Daraxonrasib
- DRUG BMS-986504
- DRUG Nivolumab + Relatlimab FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2026-07-17 |
| Est. Completion | 2032-05-20 |
| Phase | Phase 2 |
What is known before NCT07492680 opens enrollment
NCT07492680 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 5 interventions - of which Temozolomide is the first listed.
NCT07492680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07492680 about?
NCT07492680 is a clinical study titled "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)". This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial wi...
What is the current status of trial NCT07492680?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2026-07-17. Estimated completion is 2032-05-20.
What interventions are being tested in trial NCT07492680?
The interventions under investigation include: Temozolomide (DRUG), Pumitamig (DRUG), Daraxonrasib (DRUG), BMS-986504 (DRUG), Nivolumab + Relatlimab FDC (DRUG).
Who is sponsoring clinical trial NCT07492680?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07492680's enrollment target sits among peer trials
260 210th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI